Stocks / NASDAQ / Eyegate Pharmaceuticals, Inc.

Eyegate Pharmaceuticals, Inc.

Our Opinion

Eyegate Pharmaceuticals, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.

Supporting Evidence:

The following document mentions that the company conducts preclinical trials of its product CMHA-S in animal models.

“Efficacy of CMHA-S has been demonstrated in various animal pathology models:

1. Post traumatic corneal stromal ulcers (dogs and cats)
2. Corneal abrasion and alkali burn injuries (rabbits)
3. Dry eye (rabbits and dogs)”  (Page 7) Read the full document.

Company Description

EyeGate Pharma is a clinical stage pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. Its products include EGP-437 and EyeGate II Delivery System. EGP-437 for the treatment of non-infectious anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris or ciliary body. The EyeGate II Delivery System features a compact, elegant, and easy-to-use device that delivers drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect. The company was founded in 1998 and is headquartered in Waltham, MA. [Source: MarketWatch]

Company Website: